Diagnostic and Interventional Radiology
Abdominal Imaging - Review

MRI of localized prostate cancer: coming of age in the PSA era

1.

Molecular Imaging Program, National Cancer Institute National Institutes of Health, Bethesda, Maryland, USA

2.

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

3.

Center for Interventional Oncology, NCI and Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, Maryland, USA

4.

Center for Interventional Oncology, NCI and Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, Maryland, USA; Urologic Oncology Branch, NCI, NIH, Bethesda, Maryland, USA.

Diagn Interv Radiol 2012; 18: 34-45
DOI: 10.4261/1305-3825.DIR.4478-11.1
Read: 413 Downloads: 193 Published: 03 September 2019

Abstract

Prostate cancer is the most common cancer among American men. It varies widely in aggressiveness, ranging from completely indolent to highly aggressive. Currently, predicting the natural history of a particular tumor and deciding on the appropriate treatment, which might include active surveillance, surgery, radiation or hormonal therapies, are based on the condition and age of the patient as well as the presumed stage of the disease. Imaging plays an important role in staging localized prostate cancer. Magnetic resonance imaging (MRI) best depicts the zonal anatomy, with a superior soft tissue resolution providing better results for tumor localization, monitoring, and local staging. Previously, the major function of prostate MRI has been in staging, and this role remains important. In this article, we introduce the reader to the expanding roles that MRI plays in the management of localized prostate cancer.

Files
EISSN 1305-3612